MedTrace Logo

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

NCT02355028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for recurrence of active choroidal neovascularization (CNV).

Conditions

  • Exudative Age-Related Macular Degeneration

Interventions

DRUG

LHA510 ophthalmic suspension

DRUG

LHA510 vehicle

Inactive ingredients used as a placebo comparator

DRUG

Ranibizumab ophthalmic solution

For intravitreal (IVT) injection

Sponsors & Collaborators

  • Alcon, a Novartis Company

    lead INDUSTRY

Principal Investigators

  • Clinical Scientist, CA CSI, ID/Multi-TA · Novartis Institutes for BioMedical Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-03
Primary Completion
2016-09-15
Completion
2016-10-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02355028 on ClinicalTrials.gov